|
|
|
06.11.25 - 22:33
|
MacroGenics to Participate in the Stifel 2025 Healthcare Conference (GlobeNewswire EN)
|
|
|
ROCKVILLE, MD, Nov. 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside chat at the Stifel 2025 Healthcare Conference on Thursday, November 13, 2025, at 4:00 pm ET in New York, NY....
|
|
|
02.09.25 - 22:33
|
MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire EN)
|
|
|
ROCKVILLE, MD, Sept. 02, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that MacroGenics' President & Chief Executive Officer, Eric Risser, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025, at 11:30am ET in New York, NY....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.08.25 - 22:03
|
MacroGenics Appoints Eric Risser as President and Chief Executive Officer (GlobeNewswire EN)
|
|
|
ROCKVILLE, MD, Aug. 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company developing innovative antibody-based therapeutics for the treatment of cancer, today announced that effective as of August 13, 2025, Eric Risser has been appointed President, Chief Executive Officer and to the Board of Directors. Mr. Risser has served as Chief Operating Officer at MacroGenics since 2022, overseeing several key company functions and has led the Company's corporate development efforts, which have generated over $1.6 billion in non-dilutive capital since inception. Mr. Risser succeeds Scott Koenig, M.D., Ph.D. who is stepping down after serving as President and Chief Executive Officer for the past 24 years....
|
|
|
|
|
|
|
|
|
03.06.25 - 22:33
|
MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 (GlobeNewswire EN)
|
|
|
ROCKVILLE, MD, June 03, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company's management team will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10, 2025, at 8:00am ET in Miami, FL....
|
|
|
20.05.25 - 22:51
|
4 Analysts Assess Macrogenics: What You Need To Know (Benzinga)
|
|
|
Latest Ratings for MGNX
DateFirmActionFromTo Feb 2022CitigroupUpgradesNeutralBuy Feb 2022SVB LeerinkMaintainsOutperform Feb 2022BMO CapitalInitiates Coverage OnOutperform
View More Analyst Ratings for MGNX
View the Latest Analyst Ratings
read more...
|
|
|
|
|
|
|
|
|
06.05.25 - 22:33
|
MacroGenics Announces Date of First Quarter 2025 Financial Results (GlobeNewswire EN)
|
|
|
ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2025 after the market closes on Tuesday, May 13, 2025. ...
|
|
|
01.05.25 - 22:33
|
MacroGenics to Participate in Upcoming Investor Conference (GlobeNewswire EN)
|
|
|
ROCKVILLE, MD, May 01, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company's management team will participate in the following investor conference this month:...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
